CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
乳腺癌免疫治疗：驾驭癌症免疫循环
英文原题：Immunotherapies in breast cancer: harnessing the cancer immunity cycle.
查看英文原题
Immunotherapies in breast cancer: harnessing the cancer immunity cycle.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
当前诸如抗体-药物偶联物和免疫检查点阻断等疗法需要恰当的生物标志物筛选，例如 PD1 表达和 TIL（肿瘤浸润淋巴细胞）浸润程度，以筛选潜在应答者。
中文摘要
引言：由于肿瘤内部存在显著阻碍T细胞活性和功能的挑战，免疫疗法治疗乳腺癌的成功有限。 综述范围：本综述在癌症免疫循环框架下，讨论临床相关免疫治疗药物和临床试验。 专家观点：抗体药物偶联物和免疫检查点阻断等当前疗法需要适当选择生物标志物，例如PD-1表达及TIL（肿瘤浸润淋巴细胞）浸润程度，以筛选潜在应答者。HER2及其他肿瘤相关抗原一直是开发新疗法（如抗体衔接器和CAR-T 细胞）的重要参照。然而，仍需进一步研究以发现并验证新的靶抗原，从而提高治疗效力并拓宽这些方法的临床适用范围。
展开英文摘要原文
INTRODUCTION: Immunotherapies have found limited success in breast cancerdue to significant challenges within the tumor that block T-cell activity and function. AREAS COVERED: The current review discusses clinically relevant immunotherapeutics and trials within the framework of the cancer-immunity cycle.
EXPERT OPINION: Current therapies such as antibody-drug conjugates and immune checkpoint blockade require proper biomarker selection, such as PD1 expression and the degree of tumor-infiltrating lymphocyte (TIL) infiltration to subset potential responders. HER2 and other tumor-associated antigens have served as valuable benchmarks for developing novel therapies, such as antibody engagers and CAR T-cells.
However, further research is essential to identify and validate new target antigens that can enhance therapeutic efficacy and broaden the clinical applicability of these approaches.
论文信息
- 作者
- Lok V、Olson-McPeek S、Spiegelhoff G、Cortez J、Detz D、Czerniecki B
- 第一作者单位
- University of South Florida Morsani College of Medicine, Tampa, FL, USA.United States
- 通讯作者单位
- Department of Clinical Science, Moffitt Cancer Center, Tampa, FL, USA.United States
- 文献类型
- 综述
- 期刊
- Expert opinion on therapeutic targets2024 Nov
- 原文标识
- PubMed 39523444 · DOI 10.1080/14728222.2024.2427038